U.S. Multiple Sclerosis Market: Most Extreme Pricing Abuse
Uniform 10-fold U.S. Price Increases for Numerous Plummeting Brands
U.S. Multiple Sclerosis (MS) Market:
- Uniform massive U.S. brand price increases in the U.S. MS category from $15,000 to $100,000 per patient/year since Medicare Part D
- Massive U.S. MS drug price increases despite severe competition and many new similar brand and generic drugs reaching the U.S. market over the past decade-plus
- 2005: 4 similar U.S. MS drugs - each cost about $15,000/patient/year
- 2019: more than a dozen similar U.S. MS drugs - most now cost more than $100,000 patient/year
- Link to Whistleblower table of massive uniform U.S. MS drug price increases
- MASSIVE PRICE INCREASES FOR "OLD" U.S. MS BRAND DRUGS DESPITE PLUMMETING USE AND MARKET SHARE
- Not possible in a legitimate U.S competitive marketplace
- Massive "old"' brand increases fueled more pricing abuse with numerous similar new U.S. MS brand drugs reaching the market
- Severe MS brand drug pricing abuse only for Americans
- Competition prevented virtually all MS price increases outside the U.S. over the past decade-plus
- Link to Whistleblower chart of U.S. vs. European MS prices
- More than $60 billion in abusive U.S. MS drug costs over the past decade-plus for the eight (8) whistleblower case brand drugs
- More than $4 billion in abusive "pharma fees" paid to the four dominant health insurer/PBMs just for these 8 MS brand drugs
Specific U.S. MS Brand Drugs:
Biogen’s Avonex (on U.S. market since 1996)
- 2005 Reported U.S. Sales: $939 million
- 2017 Reported U.S. Sales: $1.9 billion
- U.S. Clinical Use/Prescriptions DOWN 60-70% since 2005
- 2017 U.S. Sales WITHOUT Price Increases: $322 million
- 2005 U.S. “List”/“Sticker” Price: $15,000/patient/year
- 2018 U.S. “List”/“Sticker” Price: $98,000/patient/year
- Cumulative harm since start of Part D: $12.5+ billion
Teva’s Copaxone (on U.S. market since 1996)
- 2005 Reported U.S. Sales: $782 million
- 2017 Reported U.S. Sales: $3.0 billion
- U.S. Clinical Use/Prescriptions DOWN -40-50% since 2005
- 2017 U.S. Sales WITHOUT Price Increases: $530 million
- 2005 U.S. “List”/“Sticker” Price: $15,000/patient/year
- 2018 U.S. “List”/“Sticker” Price: $90-100,000/patient/year
- Cumulative harm since start of Part D: $20 billion
Pfizer/EMD Serono's Rebif (on U.S. market since 2002)
- 2005 Reported U.S. Sales: $390 million
- 2017 Reported U.S. Sales: $1.26 billion
- U.S. Clinical Use/Prescriptions DOWN -45% since 2005
- 2017 U.S. Sales WITHOUT Price Increases: $216 million
- 2005 U.S. “List”/“Sticker” Price: $15,000/patient/year
- 2018 U.S. “List”/“Sticker” Price: $99,000/patient/year
- Cumulative harm since start of Part D: $8.4 billion
Bayer's Betaseron (on U.S. market since 1993)
- 2005 Reported U.S. Sales: $584 million
- 2017 Reported U.S. Sales: $482 million
- U.S. Clinical Use/Prescriptions DOWN -80% since 2005
- 2017 U.S. Sales WITHOUT Price Increases: $77 million
- 2005 U.S. “List”/“Sticker” Price: $15,000/patient/year
- 2018 U.S. “List”/“Sticker” Price: $103,000/patient/year
- Cumulative harm since start of Part D: $4.6 billion